Regulatory T cell (T-reg) exert negative regulatory effects in tumor immunotherapy, with immune checkpoints such as CTLA-4 and PD-1 selectively overexpressed on TME-resident T-reg cells. This evidence concerns the gene CTLA4 and neoplasm.